174 results about "Colony-stimulating factor" patented technology

A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and / or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.

The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

The invention relates to a degradable wound repair material and a preparation method thereof. The degradable wound repair material includes a matrix component and an auxiliary component, wherein the matrix component includes a protein ingredient, and the auxiliary component includes at least one of an antibacterial agent and an active factor. Specifically, the antibacterial agent is a synthetic antibacterial drug, an inorganic antibacterial agent, an organic antibacterial agent, or a natural antibacterial agent, and the active factor is at least one of the following active factors: an epidermal growth factor, an FGF vascular endothelial growth factor, a platelet-derived growth factor, a platelet activating factor, an insulin-like growth factor, a tumor necrosis factor, interleukin, colony stimulating factor-1, various bone morphogenetic proteins or transforming growth factors. By loading the antibacterial agent and active factor component on the basis of the matrix component, the degradable wound repair material provided by the invention can have biological activity on the basis of meeting degradability, can better promote wound repair, and has good anti-infection properties during use.

The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1 / CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer.

A process for generating megacaryocyte by in vitro induction to umbilical blood cell CD34+ includes in vitro amplifying the CD34+ in the culture medium containing fetal calf serum, human SCF, human TPO and / or ligand flt-3 and inducing the generation of megacaryocytes in the non-serum culture medium containing human TPO, human interleukin 3(IL-3) and / or human GM-CSF. Its advantage is high inducing efficiency.

The present invention relates to methods for mobilizing hematopoietic facilitating cells (FC) and hematopoietic stem cells (HSC) into a subject's peripheral blood (PB). In particular, the invention relates to the activation of both FLT3 and granulocyte-colony stimulating factor (G-CSF) receptor to increase the numbers of FC and HSC in the PB of a donor. The donor's blood contains both mobilized FC and HSC, and can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient. Therefore, PB containing FC and HSC mobilized by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. Alternatively, the donor's hematopoietic tissue, such as bone marrow, can be treated ex vivo to enrich selectively for FC and HSC populations by activating appropriate cell surface receptors.

The invention provides a recombinant II type herpes simplex virus vector. An ICP34.5 gene and an ICP47 gene of a wild II type herpes simplex virus HG52 strain are removed in the virus vector, and preferably a human granulocyte macrophage-colony stimulating factor (hGM-CSF) expression box is inserted into the position where the ICP34.5 gene is removed. The invention also provides a preparation method of the recombinant II type herpes simplex virus vector, a recombinant virus using the recombinant II type herpes simplex virus as a vector, a medicinal composition consisting of the recombinant II type herpes simplex virus vector and a pharmaceutically acceptable vector or excipient, and application of the recombinant II type herpes simplex virus vector in preparation of a gene medicament for treating tumors. As the ICP34.5 gene is removed in the recombinant II type herpes simplex virus vector provided by the invention, the oncolysis virus is safe and can selectively grow and propagate in tumor cells; the ICP47 gene is removed to promote immune response and enhance oncolysis activity; and the curative effect of the recombinant II type herpes simplex virus vector is superior to that of the conventional recombinant I type herpes simplex virus vector, and the recombinant II type herpes simplex virus vector has high safety.

A tumor vaccine which comprises a microparticle or a lysate prepared from a solidified tumor material selected from the group consisting of a tumor tissue, a tumor cell, and a component thereof, and at least one cytokine and / or cytokine-inducing agent (e.g., a granulocyte-macrophage-colony stimulating factor and / or interleukin-2 and the like), and optionally an adjuvant. The vaccine can be easily prepared and widely applied for prevention of recurrence, inhibition of metastasis and therapeutic treatment regardless of a type of a tumor, and has excellent antitumor effect.

This application concerns novel methods which enable or improve the ability of molecules, particularly large molecules, to cross the blood-brain barrier, the blood-eye barrier, and / or the blood-nerve barrier and therefore be of improved diagnostic and / or therapeutic use in humans and other mammals. These methods involve perispinal administration of imaging agents without direct intrathecal injection. Perispinal administration is defined as administration of the molecule into the anatomic area within 10 cm of the spine. Perispinal administration results in absorption of the imaging agent into the vertebral venous system. The vertebral venous system is capable of transporting molecules into the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine, the spinal cord, the vertebral bodies, the dorsal root ganglia, and the nerve roots via retrograde venous flow, thereby bypassing the blood-brain barrier and similar barriers and delivering the molecules to the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine (including the vertebral bodies), the spinal cord, the dorsal root ganglia, or the nerve roots. This method may be utilized for a wide variety of diagnostic agents, including, but not limited to biologics, monoclonal antibodies, fusion proteins, monoclonal antibody fragments, antibodies to tumor antigens, hormones, cytokines, anti-cytokines, interleukins, anti-interleukins, interferons, colony-stimulating factors, cancer chemotherapeutic agents, growth factors, anti-virals and antibiotics, including those which are radiolabeled, iodinated, or otherwise altered to facilitate diagnostic imaging. Included in these novel methods are perispinal delivery of amyloid imaging agents, and other ligands radiolabeled with [11C] or [18F] to faciliate PET imaging of the brain.

A process for preparing the recombinant human granulocyte colony stimulating factor includes such steps as fermenting culture of DH5 alpha-PBV220-hGCSF strain, separating cytoryctes, washing, modifying renaturation, ultrafilter, the second renaturation, and chromatography. Its advantages are high purity and high activity.

The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3.

Described is the modulation of the neovascularization and / or growth of collateral arteries and / or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and / or the growth of collateral arteries and / or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding a CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding a CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and / or collateral growth of collateral arteries and / or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and / or the growth of collateral arteries and / or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and / or the growth of collateral arteries and / or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors.

The invention discloses a synthetic aperture radar (SAR) image quality evaluation method based on contrast sensitivity characteristics. The method can effectively eliminate noise interference of a high frequency part in an SAR image by utilizing similarity of wavelet decomposition and contrast sensitivity colony stimulating factor (CSF) function space frequency band pass. Simultaneously, the method is simple, convenient and accurate to calculate, free from referring the SAR image and capable of evaluating the image quality comprehensively and effectively only according to an HVSR parameter index. The method can be applied to the SAR image obtained by airborne or satellite borne synthetic aperture radar. A subjective no-reference image type SAR image quality evaluation model is established through the multichannel characteristics of contrast sensitivity in human eye vision and by combining a method of wavelet transform in image processing, and evaluation of the SAR image by real subjectivity is achieved. According to the SAR image quality evaluation method based on the contrast sensitivity characteristics, the defect that existing SAR image quality evaluation lacks subjective characteristics is remedied, and solid technical support for evaluating the SAR image and improving the SAR image quality in future is established.

Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and / or a tumor suppressor(s).

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

This invention relates to a method for producing recombined human granular leukocyte colony stimulating factors including: fermenting, breaking bactrriums, extracting occlusion bodies, chromatographing with molecular sieves, renaturating, exchanging anions, exchanging cations to get the raw fluid, in which, BL21 is selected as the host bacterium and the engineering bacterium type is got in high expression volume, quick reproduction and stable passage, several purification steps greatly reduce the residural toxin in the bacterium and the specific activity is increased greatly, a dialysis method is applied for the renaturation to reduce the concentration of the denaturalization agent steadily so the renaturation rate is at high level.

This invention relates to a preparation method of recombinant human granulocyte colony stimulating factor (rhG - CSF). It includes cracking liquid of inclusion bodies, composition of renaturation liquid, cracking and renaturation method.The renaturation liquid composed by guanidine hydrochloride ( Guanidine - HCl),urea, trihydroxymethyl aminomethane hydrochloride ( Tris - HCl), cysteine, cystine and glycerol.

The invention relates to the modification of a non-human animal by a humanized gene, in particular to a construction method of a non-human animal modified by a humanized cell factor IL3 (interleukin3)gene, and application of the construction method in the biological medicine field, and in particular to an animal model which expresses a humanized IL3 protein. In certain examples, the genetic modification non-human animal which expresses the human IL3 protein also contains IL2rg deletion and / or contains the humanization of more cell factor, including CSF2 (colony stimulating factor 2) and thelike. The invention also provides a construction method for the above animal model and the application of the construction method in the biological medicine field.

The invention discloses a use of recombinant human granulocyte macrophage colony stimulating factor in the preparation of treatment or prevention hepatitis B, while includes simultaneous or successive given recombinant human granulocyte macrophage colony stimulating factor and genetic engineering hepatitis B vaccine for the prevention or treatment of hepatitis B.

The invention provides a method for using homotype double functional cross linking agent with epoxy radicals for protein and polypeptide cross bonding, the cross linking agent used by the present invention can realize an ideal reaction velocity for the cross bonding between proteins and polypeptides with good controllability. When applied to the hemoglobin cross bonding under controlled conditions, the method can raise the yield for inter-molecule cross bonding to above 90%.

Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and / or a tumor suppressor(s).

The present invention discloses one kind of secretion vector of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and its simple purification method, host cell transformed with the secretion vector, as well as the method of fermentation with the recombinant pichia yeast engineering strain of the said expression vector to express rhGM-CSF. The present inention replaces colibacillus occlusion body expression system with yeast secreting expression sytem and has no need of renaturation of target protein rhGM-CSF, biological specific activity up to 3.4E7 unit / mg protein and less toxic side effect. Therefore, the rhGM-CSF of the present invention has high yield, simple purification process, low cost and less toxic side effect.